Yesterday was the third day of the American Society of Hematology (ASH) 2011 Annual Meeting in San Diego, and it was packed full with multiple myeloma-related presentations. Presentations started early in the morning and continued through the afternoon.

The morning presentations about potential new myeloma therapies will be covered in this update, and presentations from the rest of the day will be covered in additional updates.

MLN9708

During the first talk of the day, Dr. Paul Richardson from the Dana-Farber…

Results from a number of multiple myeloma studies were presented yesterday during the second day of the American Society of Hematology (ASH) 2011 annual meeting in San Diego.

Predicting Response To Immunomodulatory Drugs

During an oral presentation and a poster presentation yesterday, researchers discussed the role of the protein cereblon in the treatment of myeloma.  Results from one study (abstract) in myeloma cell lines suggested that cereblon plays a key role in whether multiple myeloma patients respond to the…

In a recent editorial published in the journal Haematologica, two Spanish myeloma experts, Dr. Jesús San-Miguel and Dr. Maria-Victoria Mateos from the University Hospital of Salamanca, review the progress that has been made in the treatment of multiple myeloma.

More importantly, Drs. San-Miguel and Mateos propose several actions they believe will bring the medical community closer to a cure for myeloma.

These actions include achieving and maintaining the best possible response early in the treatment of the disease, using advanced…

“Daddy, do you remember that Christmas when you were bald?” my eight-year old daughter Lizzie recently asked me.

Until that point we had been talking about the eagles that occasionally glided in the skies above the lake next to our home in the Ozarks of southwestern Missouri.

“Uh… yes,” I chuckled, amused at her segue from bald eagles to the cue-ball that I had donned three years earlier during my chemotherapy treatments for myeloma. “Do you remember when I was…

A team of British and German researchers have identified specific areas of the human genome that consistently differ between people with multiple myeloma and people who do not have the disease.

The new findings, summarized in a research article published yesterday, help explain why the risk of developing myeloma seems to be higher in some families than in others.

Moreover, by clearly identifying regions of the human genome linked to an increased risk of myeloma, the European research could lead…